Clathrin-mediated endocytosis (CME) regulates the uptake of cell surface receptors, as well as 15 their downstream signaling activities. We recently reported that signaling reciprocally regulates 16 CME in cancer cells and that the crosstalk can contribute to cancer progression. To further explore 17 the nature and extent of the crosstalk between signaling and CME in cancer cell biology, we 18 analyzed a panel of oncogenic signaling kinase inhibitors for their effects on CME. Inhibition of 19 several kinases selectively affected CME function in cancer cells. Among these, ERK1/2 inhibition 20 selectively inhibited CME in cancer cells by decreasing the rate of CCP initiation. We identified 21 an ERK1/2 substrate, the FCH/F-BAR and SH3 domain-containing protein, FCHSD2, as being 22 30 31 Keywords: Epidermal growth factor receptor (EGFR); signal transduction; non-small cell lung 32 cancer (NSCLC); Nervous Wreck (Nwk) 33 34 35 3 Significance 36
essential for the ERK1/2-dependent effects on CME and CCP initiation. ERK1/2 phosphorylation 23 activates FCHSD2 and regulates EGFR endocytic trafficking as well as downstream signaling 24 activities. Loss of FCHSD2 activity in non-small-cell lung cancer cells leads to increased cell 25 surface expression and altered signaling downstream of EGFR, resulting in enhanced cell 26 proliferation and migration. The expression level of FCHSD2 is positively correlated with higher 27 cancer patient survival rate, suggesting that FCHSD2 negatively affects cancer progression. These 28 findings provide new insight into the mechanisms and consequences of the reciprocal regulation 29 of signaling and CME in cancer cells. 49 50 Introduction 51 Cancer progression involves tumor cell proliferation and metastasis driven, in part, by 52 altered intracellular signaling downstream of plasma membrane receptors (1, 2) . In tumor cells, 53 signaling activities can be altered by dysregulated endocytic trafficking that increases receptor 54 recycling and decreases lysosomal targeting and degradation (3) (4) (5) . Hence, a link between 55 endocytosis and cancer behavior has been suggested (3, (6) (7) (8) . Clathrin-mediated endocytosis 56 (CME) is the major endocytic pathway that determines the rates of internalization of plasma 57 membrane receptors, regulates their cell surface expression, and controls their downstream 58 signaling activities (9, 10) . Despite the well-known fact that CME can regulate intracellular 59 signaling pathways (11), whether and how signaling can feedback to regulate CME during cancer 60 cell progression has been less studied. 61 CME occurs when clathrin-coated pits (CCPs) assemble on the cell surface, concentrate 62 cargo molecules (i.e. receptors and their bound ligands), invaginate and undergo membrane fission 63 catalyzed by the GTPase dynamin to release clathrin coated vesicles into the cytosol. Once 64 considered a constitutive process, recent studies have demonstrated that CME can be dynamically 65 regulated in response to cargo and downstream signaling pathways (12) (13) (14) (15) . For example, in non-66 small cell lung cancer (NSCLC) cells, dynamin-1 (Dyn1), the neuron-enriched isoform, is 67 frequently overexpressed and can be activated downstream of the Akt/GSK3β signaling cascade, 68 resulting in increased rates of CCP initiation and dysregulated CCP maturation (15) . Moreover, 69 the clathrin light chain isoform b (CLCb), which functions primarily to regulate clathrin assembly 70 and is also neuronally-enriched (16, 17) , is specifically upregulated in NSCLC cells (18) . CLCb-71 dependent alterations in CME lead to Dyn1 activation via increased Akt/GSK3β phosphorylation 72 associated with APPL1-positive signaling endosomes (18) . The crosstalk between signaling and 73 5 CME contributes to abnormal trafficking of epidermal growth factor receptors (EGFRs) and 74 altered downstream signaling, leading to enhanced cancer cell migration and metastasis (18) . 75 Accordingly, it is important to further understand the nature and extent of interactions between 76 CME and intracellular signaling in cancer cell biology. 77 To address this issue, we analyzed a panel of oncogenic signaling kinase inhibitors for their 78 differential effects on CME in several human non-cancerous and cancer cells. We identified 79 ERK1/2 activity as being selectively required for rapid CME and CCP initiation in cancer cells 80 and FCHSD2 (Nervous Wreck, in Drosophila) as the downstream kinase substrate responsible 81 these effects. Our study provides new insight into the mechanisms and consequences of the 82 reciprocal regulation of signaling and CME in cancer cells. 83 
84

Results
85
Oncogenic Signaling Differentially Affects CME in Cancer Cells 86 Recent studies have shown that the crosstalk between intracellular signaling and CME can 87 affect cancer progression and metastasis (8, 18) . Thus, it is important to determine the extent of 88 this crosstalk as well as the signaling pathways that impinge on the regulation of CME in cancer 89 cells. To this end, we prioritized a set of kinases and GTPases that are often implicated in cancer-90 relevant signaling pathways and assessed the effects of their validated inhibitors (19) on transferrin 91 receptor (TfnR) endocytosis, a canonical marker for the quantification of CME (20, 21) . Initially, 92 we chose non-cancerous ARPE-19 cells, which have been routinely used to study TfnR 93 endocytosis (20) and compared these to H1299 NSCLC cells, which exhibit crosstalk between 94 signaling and CME (15, 18) . 95 Strikingly, 10 of the 21 inhibitors we screened differentially affected CME in H1299 vs 96 ARPE cells ( Figure S1 ). This included inhibition of Akt, which we previously showed functions 97 through an Akt/GSK3β signaling cascade to activate Dyn1 and enhance endocytosis in H1299 and 98 A549 NSCLC cells (15, 18, 22) . To further validate these findings, we extended the functional 99 comparison of these 10 inhibitors to more closely matched cancerous and non-cancer cell lines. 100 We used another NSCLC cell line, HCC4017, together with the syngeneic non-tumorigenic HBEC 101 line, HBEC30KT, derived from the same patient (23). In addition, we compared the breast cancer 102 cell line, MDA-MB-231 with normal human mammary epithelial cells, MCF10A (24). Consistent 103 with our initial screen, inhibition of a subset of these kinases significantly reduced CME activity 104 in most cancer cell lines, without affecting CME in their non-cancerous counterparts ( Figure 1A ). 105 These findings reveal the unexpected differential regulation of CME in cancer cells by distinct 106 intracellular signaling pathways. 107 Inhibiting some of these kinases selectively enhanced CME in non-cancerous vs. cancer 108 cells. GSK3b enhanced rates of CME in most cell lines tested, presumably through activation of 109 Dyn1 (15, 22) . Interestingly, inhibition of myosin light chain kinase (MLCK) and Rho kinase 110 (ROCK) accelerated endocytosis in a subset of non-cancer cell lines, while inhibiting CME in a 111 subset of cancer cells. As these kinases control the actin cytoskeleton, these results could reflect 112 known cell-type differences in the role of actin in cancer vs non-cancer cells (25, 26) . While it will 113 be important to investigate how each of these signaling pathways impinge on CME, we chose to 114 focus our further studies on ERK signaling as the EGFR/Ras/ERK1/2 pathway is a major driver 115 of, and therapeutic target for multiple cancers (27) (28) (29) (30) . Inhibition of ERK1/2 selectively inhibits 116 CME in all cancer cell lines tested without affecting CME in several non-cancerous cell lines 117 ( Figure 1B) . For further studies we chose ARPE-19 and H1299 cells, as well as the syngeneic pair, 118 HCC4017 and HBEC30KT. 119 120 ERK1/2 Specifically Regulates CME in Cancer Cells 121 ERK1/2 signaling, downstream of EGFR and Ras, is highly activated in many cancers. To 122 confirm that ERK1/2 activity is selectively involved in the regulation of CME in cancer cells we 123 used a second ERK1/2 inhibitor (SCH772984), as well as a well-characterized inhibitor of the 124 essential upstream kinase, MEK (GSK1120212). As expected, these ERK1/2 signaling inhibitors 125 efficiently decreased ERK1/2 phosphorylation (Figure 2A and S2A) . Importantly, they also 126 specifically inhibited CME both in H1229 relative to ARPE-19 cells ( Figure 2B ) and in HCC4017 127 relative to HBEC30KT cells ( Figure S2B ). 128 CME is a multistep process that involves CCP initiation, stabilization, maturation and 129 finally fission. To determine which step(s) of CME were affected upon ERK1/2 inhibition, we 130 analyzed CCP dynamics using quantitative total internal reflection fluorescence microscopy 131 (TIRFM) (15, 18) in ARPE-19 and H1299 cells stably expressing EGFP-clathrin light chain a 132 (EGFP-CLCa), and in HCC4017 cells stably expressing SNAP-CLCa. As expected, CCP 133 dynamics were unchanged in the ARPE-19 cells upon inhibitor treatment ( Figure 2C ). However, 134 inhibition of ERK1/2 signaling dramatically reduced the rate of CCP initiation without 135 significantly altering the lifetime distribution or median lifetimes of CCPs in both H1299 cells 136 ( Figure 2D ) and HCC4017 cancer cells ( Figure S2C ). These data indicate that ERK1/2 signaling 137 differentially regulates the first key step of CME (i.e. CCP initiation) (31) in cancer cells. 138 139 FCHSD2 Regulates CME in Cancer Cells 140 ERK1/2 kinases are ubiquitously expressed serine/threonine kinases that regulate diverse 141 biological processes (32-35) by phosphorylating multiple substrates (36). We screened the 142 literature for ERK1/2 substrates and identified FCHSD2 (37), the human orthologue of Nervous 143 Wreck (Nwk) in Drosophila, which has been implicated in membrane remodeling (38) and the 144 regulation of growth factor signaling (39, 40) at the synapse. While thus far not studied in the 145 context of CME in mammalian cells, FCHSD2 was of interest, because it encodes an N-terminal 146 F-BAR domain predicted to initiate membrane curvature and two C-terminal SH3 domains 147 proposed to interact with the components of the actin and CME machinery (41). 148 To test its potential role in CME, we first investigated the effects of efficient siRNA-149 mediated knockdown of FCHSD2 ( Figure 3A and S3A) in non-cancerous and cancer cells. Like 150 ERK1/2 inhibition, depletion of FCHSD2 did not significantly alter CME activities in non-151 tumorigenic ARPE-19 or HBEC30KT cells, but potently inhibited CME in H1299 and HCC4017 152 NSCLC cells ( Figure 3B and S3B). FCHSD2 depleted cancer cells were no longer sensitive to 153 ERK1/2 inhibition ( Figure 3C and S3C), even though they remained sensitive to SP600125 ( Figure   154 S3C), a JNK inhibitor that also specifically affects CME in cancer cells (see Fig. 1A ). These data 155 suggest that FCHSD2 might be the CME-relevant downstream target of ERK. Consistent with this, 156 like ERK inhibition, knockdown of FCHSD2 specifically inhibited the rate of CCP initiation 157 without affecting CCP lifetimes ( Figure 3D ). The reduced rate of CCP initiation in FCHSD2-158 depleted cells was now insensitive to ERK1/2 inhibition. Together, these data demonstrate that 159 FCHSD2 plays a role in CME, especially in CCP initiation, and suggest that it functions as a 160 relevant downstream effector of ERK1/2 kinases. 161 162
ERK1/2 Directly Regulates FCHSD2-Mediated CME in Cancer Cells
163
The phosphorylation of FCHSD2 on S681 within a canonical ERK phosphorylation motif 164 (PXSP) was identified in a large-scale screen for ERK2 substrates using an analogue-sensitive 165 ERK2 mutant (37). We first confirmed phosphorylation of this site in EGF-treated HCC4017 cells 166 by phospho-proteomic analysis ( Supplemental Table 1 ). To test whether FCHSD2 was indeed the 167 ERK1/2 substrate responsible cancer cell-specific regulation of CME, we performed FCHSD2 168 siRNA-mediated knockdown in H1299 and HCC4017 cells followed by reconstitution with either 169 wild-type FCHSD2 (FCHSD2 WT -Myc), a mutant that cannot be phosphorylated by ERK1/2 170 (FCHSD2 S681A -Myc), or with a phosphomimetic mutant (FCHSD2 S681E -Myc) at near endogenous 171 levels ( Figure 4A ). Reconstitution of FCHSD2 siRNA-depleted H1299 or HCC4017 cells with 172 FCHSD2 WT -Myc rescued CME activity, which was again sensitive to ERK1/2 inhibition ( Figure   173 4B, dark gray bars). In contrast, reconstitution with non-phosphorylatable FCHSD2 S681A -Myc 174 failed to restore CME or sensitivity to ERK1/2 inhibition ( Figure 4B , black bars). Strikingly, 175 reconstitution with FCHSD2 S681E -Myc resulted in rates of CME higher than in control cells, and 176 importantly resistance to ERK1/2 inhibition ( Figure 4B , twill bars). Together these data provide 177 strong evidence that phosphorylation of FCHSD2 is indeed required for the ERK1/2-dependent 178 effects on CME in cancer cells. 179 Reconstitution of FCHSD2-depleted cells with FCHSD2 WT -Myc, but not the 180 FCHSD2 S681A -Myc mutant, restored ERK1/2 dependent rates of CCP initiation ( Figure 4C Figure 5A ). However, EGFR uptake in HBEC30KT cells was more 195 sensitive to ERK1/2 inhibition and FCHSD2 knockdown than TfnR uptake (compare Fig. 5A Figure 6A and B). Reintroducing FCHSD2 WT -Myc, but not FCHSD2 S681A -Myc, again 218 suppressed these signaling activities ( Figure 6A and B). Expression of FCHSD2 S681E -Myc also 219 reduced signaling activities back to control levels ( Figure 6A and B). These findings suggest that 220 the crosstalk between ERK1/2 kinases and FCHSD2 contributes to the endocytic trafficking of 221 EGFRs and reciprocally regulates its downstream signaling activities. 222 EGFR signaling affects both cancer cell proliferation and migration (44). Therefore, we 223 examined the effects of FCHSD2-dependent alterations in the endocytic trafficking of EGFR and 224 its signaling activities on these cancer cell behaviors. Loss of FCHSD2 increased the rates of 225 proliferation ( Figure 7A ) in the NSCLC cells. These effects were reversed upon reconstitution with 226 FCHSD2 WT -Myc or FCHSD2 S681E -Myc, but less so by the FCHSD2 S681A -Myc ( Figure 7A ). 227 Similarly, EGF-dependent migration through transwell filters was enhanced by siRNA 228 knockdown of FCHSD2 ( Figure. Finally, we examined the relationship between FCHSD2 expression and survival by mining 233 clinical data and found that patients with relatively high FCHSD2 expression had significantly 234 better survival rates than those in the low-expression group ( Figure 7D ). Together, these data 235 suggest that FCHSD2 functions as a negative regulator for cancer aggressiveness. The reciprocal crosstalk between signaling and CME in cancer cells contributes to 239 abnormal trafficking of surface receptors and altered downstream signaling (3, 7, 18) . These 240 findings have led to the hypothesis that CME can be 'adapted' by cancer cells to support enhanced 241 tumor cell proliferation and metastasis (8). Here we explored the scope of this crosstalk and found 242 that CME can be differentially regulated in cancer cells by several oncogenic signaling kinases. 243 These studies reveal a more extensive crosstalk between signaling and CME than previously 244 appreciated. Further studies are needed to dissect the direct or indirect roles and relevant substrates 245 for the many signaling pathways that selectively impinge on CME in cancer cells. 246 We focused on the effects of ERK given its importance as a major driver and therapeutic 247 target for multiple cancers (27) (28) (29) (30) . ERK1/2 inhibition decreased the rates of CME of TfnR and 248 EGFR in cancer cells by specifically inhibiting CCP initiation, the critical first step in CME. 249 ERK1/2 accelerates CME and CCP initiation rates through phosphorylation and activation of 250 FCHSD2. When activated, FCHSD2 negatively regulates EGFR signaling, cell proliferation and 251 migration in NSCLC cells. This study, together with our previous findings (15, 18), strongly 252 supports the concept of adaptive CME and reveals a new mechanism for the reciprocal regulation 253 of signaling and CME in cancer cells. 254 Although previously not studied in this context, the domain structure of FCHSD2 as well 255 as its known protein interactions (Supplemental Figure 4 ) are suggestive of a role in CME (47, 256 48). FCHSD2 is a member of the mild curvature-generating F-BAR family of proteins (49), whose 257 prototypical members, FCHo1/2, have been shown to function in the early stages of CCP initiation 258 and stabilization (41). Here we show that when activated downstream of ERK1/2, FCHSD2 is 259 selectively required for CCP initiation in NSCLC cells. Further studies are needed to probe the 260 underlying mechanisms. 261 Many F-BAR proteins contain SH3 domains (41, 50) and FCHSD2 encodes two that 262 interact with other components of the endocytic machinery, including dynamin, Wiskott-Aldrich 263 Syndrome protein (WASp) and intersectin1/2 (ITSN1/2) (39, 51). Which of these partners, if any, 264 are required for FCHSD2 function in CCP initiation remains to be determined. In this regard, a 265 recent study, which appeared while preparing this manuscript, reported a role for FCHSD2 in CME 266 using HeLa cells as model (52). These authors showed that FCHSD2 is recruited to CCPs through 267 interactions with intersectin and speculated that it functioned to regulate actin assembly during 268 intermediate stages of CME. While there are some discrepancies between the two studies, with 269 regard to the stage at which FCHSD2 functions, in general the results are complementary and 270 confirm a role for FCHSD2 in CME. 271 Much more is known about Nervous Wreck (Nwk), the Drosophila orthologue of 272 FCHSD2, although it has been studied exclusively in the context of endocytic trafficking and bone 273 morphogenic protein (BMP) signaling at neuromuscular junctions (39, 40, 51 required for activation of Nwk. We found that ERK1/2-mediated phosphorylation of FCHSD2 on 286 S681 is critical for its activity. This phosphorylation site, which resides in the C-terminal region 287 distal to SH3b, is not conserved in Nwk (Supplemental Figure 4) and may reflect an additional 288 level of regulation that renders mammalian FCHSD2 activity responsive to extracellular signaling. 289 We speculate that phosphorylation of S681 either directly disrupts the autoinhibitory interactions 290 of the adjacent SH3b domain or indirectly increases the binding affinity of SH3b domain ligands 291 to relieve the autoinhibition. Alternatively, phosphorylation may alter FCHSD2 interactions with 292 other proteins independently of its own activation. Clearly, further investigation is needed to test 293 these hypotheses regarding the regulation of FCHSD2. 294 Our results extend FCHSD2 function to outside the nervous system and to earlier stages of (39, 40, 51) ). Thus, FCHSD2 activity may play a role in buffering EGFR signaling in normal cells, 322 as we observed in EGF-dependent HBEC30KT cells. In this scenario, its specific upregulation in 323 cancer cells could reflect a compensatory mechanism to counteract the detrimental effects of 324 hyperactive EGFR signaling. Indeed, high levels of FCHSD2 expression correlate with better 325 survival rates in human lung cancer patients. 326 Overall, our study reveals extensive crosstalk between signaling and clathrin-mediated 327 endocytosis, often specific to cancer cells. Based on our findings reported here and elsewhere (64, 328 65), we suggest that cancer cells adapt this crosstalk as a determinant for tumor progression. These which was used as internal controls, according to the manufacturers' instructions. For FCHSD2 373 we used #PA5-58432 (Thermo Fisher Scientific), which detected an ~85 kD band that was 374 specifically knocked down by siFCHSD2 treatment at 1:500 dilution. Note that the manufacturer's 375 data shows a 100 kD band, which we also detected, but this band did not respond to siRNA 376 knockdown. The calculated MW for the 740aa variant of FCHSD2 (Accession number O94868) 377 is ~84 kD. Horseradish peroxidase (HRP)-conjugated secondary antibodies (#G21234 and # 378 G21040, Thermo Fisher Scientific) were used according to the manufacturers' instructions. 379 Quantitative analysis was performed by using ImageJ software (NIH). For EGF-dependent 380 signaling, the H1299 and HCC4017 cells (5×10 5 cells) were seeded in 6-well plates containing 381 RPMI 1640 with 10% FCS. Eight hours after seeding, cells were washed three times with PBS and 382 starved in RPMI 1640 without FCS for 16 h. The cells then were untreated or treated with 20 ng/ml 383 of EGF for 10 min. After the EGF treatment, cells were washed three times with PBS and 384 harvested/resuspended in 150-200 µl of reducing Laemmli sample buffer, and the cell lysates were 385 subjected to Western blotting as described above. Cells that had migrated to the lower surfaces of the membrane were fixed with ice-cold methanol 469 (Pharmco) for 10 min and stained with 0.5% crystal violet (MilliporeSigma) for 15 minutes. After 470 imaging, cells were washed three times with ddH2O and incubated in 1% SDS solution 471 (MilliporeSigma) for 5 min at room temperature and the number of cells quantified by the 472 absorbance at 595 nm.
386
TIR-FM and Image Data Analysis
473
Analysis of Kaplan-Meier Survival Data
474
NSCLC patient survival data was downloaded from the Kaplan Meier plotter database (68). 475 Analysis of NSCLC patients was performed in FCHSD2 high and low expression cohort. P value 476 was calculated by logrank test (68).
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